Status:
RECRUITING
Overfeeding Induced Fat-tissue Stimulation
Lead Sponsor:
German Diabetes Center
Collaborating Sponsors:
Yale University
Conditions:
Lipid-induced Insulin Resistance
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
Type 2 diabetes is the most common metabolic disease worldwide, characterized by hyperglycemia, decreased whole body insulin sensitivity, and white adipose tissue (WAT) dysfunction. A key factor in it...
Eligibility Criteria
Inclusion
- Age between 18 and 40 years
- BMI \< 29 kg/m2
- Sport inactive (\<1x /week)
- Capacity to consent
Exclusion
- Diabetes mellitus disease
- Acute coronary heart syndrome (myocardial infarction, unstable angina pectoris, stroke or transient ischemic attack in the last 3 months before study participation)
- Acute infectious disease
- Taking blood glucose-lowering drugs
- Diseases or drugs affecting the immune system and allergies to drugs used in the study
- Drugs with potential metabolic effects
- Chronic liver disease (hepatitis, gallbladder disease, elevated liver enzymes (ALT \> 300 U/L))
- Chronic inflammatory bowel diseases
- Rheumatic diseases
- Hyper- or hypothyroidism of the thyroid gland
- Renal insufficiency, administration of iodine-containing contrast media in the last 2 days
- Chronic lung diseases
- cancerous diseases
- Addictive diseases, psychiatric diseases
- Pregnancy, breastfeeding
- Shift workers
- Anemia (Hb \<12 g/dl)
- Disorders of hemostasis
- Regular use of antithrombotic drugs
- Alcohol consumption, smoking
- Conditions that do not permit an MRI examination
Key Trial Info
Start Date :
January 31 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT06193668
Start Date
January 31 2024
End Date
December 31 2030
Last Update
March 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Georgia Xourafa
Düsseldorf, North Rhine-Westphalia, Germany, 40225